Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001493152-25-004856
Filing Date
2025-02-04
Accepted
2025-02-04 16:05:47
Documents
5

Document Format Files

Seq Description Document Type Size
1 form424b5.htm 424B5 486080
2 form424b5_001.jpg GRAPHIC 65083
3 form424b5_002.jpg GRAPHIC 157607
4 form424b5_003.jpg GRAPHIC 86918
5 form424b5_004.jpg GRAPHIC 102932
  Complete submission text file 0001493152-25-004856.txt   1055561
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 424B5 | Act: 33 | File No.: 333-276650 | Film No.: 25588129
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)